NKTR vs VMC · rev $21.0M vs P/E 35, rev $7.94B
Nektar Therapeutics (NKTR) versus Vulcan Materials Company (VMC) — a side-by-side from cached financials, not a winner call.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Vulcan Materials Company (VMC) is a building materials company listed on NYSE.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
Latest reported VMC revenue for 2025-12-31 was $7.94B. Net income was $1.08B. Revenue was up 7.1% from 2024-12-31 to 2025-12-31. VMC currently screens at market cap $38.25B and trailing P/E 34.9.
NKTR currently screens at market cap $307.2M. VMC currently screens at market cap $38.25B and trailing P/E 34.9.
Not investment advice. Open the NKTR and VMC stock pages for the full models.
Not investment advice.